Shingrix is challenging Merck & Co.’s Zostavax to become the shingles vaccine of choice in the US and beyond. Trials have suggested that Shingrix can offer more protection than Zostavax and ...

Shingrix has been touted as a potential blockbuster as study results suggest it could offer greater protection against the shingles virus, also known as herpes zoster, than Merck & Co's rival ...